DNA Link, Inc. (KOSDAQ:127120)

Market Cap	158.85B
Revenue (ttm)	15.91B
Net Income (ttm)	-10.80B
Shares Out	22.95M
EPS (ttm)	-542.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	452,064
Average Volume	253,396
Open	7,200.00
Previous Close	7,260.00
Day's Range	7,090.00 - 7,720.00
52-Week Range	1,775.00 - 7,720.00
Beta	-0.01
RSI	57.84
Earnings Date	Mar 21, 2025

About DNA Link

DNA Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 81
• Stock Exchange: KOSDAQ
• Ticker Symbol: 127120

Financial Performance

In 2024, DNA Link's revenue was 15.91 billion, a decrease of -27.52% compared to the previous year's 21.95 billion. Losses were -10.80 billion, 93.0% more than in 2023.